MY207909A - Solid pharmaceutical formulations of 6-(2-chloro-6-methylpyridin-4-yl)-5-(-4-fluorophenyl)-1,2,4-triazin-3-amine - Google Patents
Solid pharmaceutical formulations of 6-(2-chloro-6-methylpyridin-4-yl)-5-(-4-fluorophenyl)-1,2,4-triazin-3-amineInfo
- Publication number
- MY207909A MY207909A MYPI2022002810A MYPI2022002810A MY207909A MY 207909 A MY207909 A MY 207909A MY PI2022002810 A MYPI2022002810 A MY PI2022002810A MY PI2022002810 A MYPI2022002810 A MY PI2022002810A MY 207909 A MY207909 A MY 207909A
- Authority
- MY
- Malaysia
- Prior art keywords
- pharmaceutical formulations
- methylpyridin
- triazin
- fluorophenyl
- chloro
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Solid pharmaceutical formulations including AZD4635 are described. The solid formulations can include a polymeric stabilizer (e.g., a polyvinylpyrollidone), an ionic surfactant (e.g., sodium docusate), and a non-ionic surfactant (e.g., a poloxamer).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962942417P | 2019-12-02 | 2019-12-02 | |
| PCT/EP2020/084160 WO2021110697A1 (en) | 2019-12-02 | 2020-12-01 | Solid pharmaceutical formulations of 6-(2-chloro-6-methylpyridin-4-yl)-5-(-4-fluorophenyl)-1,2,4-triazin-3-amine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY207909A true MY207909A (en) | 2025-03-27 |
Family
ID=73698812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2022002810A MY207909A (en) | 2019-12-02 | 2020-12-01 | Solid pharmaceutical formulations of 6-(2-chloro-6-methylpyridin-4-yl)-5-(-4-fluorophenyl)-1,2,4-triazin-3-amine |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US12502355B2 (en) |
| EP (1) | EP4069199B1 (en) |
| JP (1) | JP7731883B2 (en) |
| KR (1) | KR20220109430A (en) |
| CN (1) | CN114727963B (en) |
| AR (1) | AR120653A1 (en) |
| AU (1) | AU2020395495B2 (en) |
| BR (1) | BR112022010626A2 (en) |
| CA (1) | CA3162154A1 (en) |
| ES (1) | ES2977281T3 (en) |
| IL (1) | IL293268A (en) |
| MX (1) | MX2022006662A (en) |
| MY (1) | MY207909A (en) |
| PL (1) | PL4069199T3 (en) |
| TW (1) | TWI870511B (en) |
| WO (1) | WO2021110697A1 (en) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20130814A1 (en) * | 2006-08-30 | 2013-08-08 | Novartis Ag | BENZIMIDAZOLYL PYRIDYL ETHER SALTS AND FORMULATIONS CONTAINING THEM |
| ES2579949T3 (en) * | 2010-02-05 | 2016-08-17 | Heptares Therapeutics Limited | 1,2,4-triazin-4-amine derivatives |
| BR112012026843A2 (en) | 2010-04-20 | 2016-07-12 | Cipla Ltd | composition, pharmaceutical composition, process for preparing a pharmaceutical composition, use of a composition and method for treating HIV |
| NZ708272A (en) * | 2013-01-22 | 2020-07-31 | Hoffmann La Roche | Pharmaceutical composition with improved bioavailability |
| WO2015152433A1 (en) * | 2014-03-31 | 2015-10-08 | Hanmi Pharm. Co., Ltd. | Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same |
| MX2017011469A (en) * | 2015-03-10 | 2018-01-23 | Shionogi Inc | Solid dispersions. |
| MX2019015885A (en) * | 2017-06-22 | 2020-09-10 | Novartis Ag | Antibody molecules to cd73 and uses thereof. |
| WO2020065036A1 (en) * | 2018-09-27 | 2020-04-02 | Iteos Therapeutics S.A. | Use of an inhibitor of an ent family transporter in the treatment of cancer and combination thereof with an adenosine receptor antagonist |
-
2020
- 2020-12-01 KR KR1020227022040A patent/KR20220109430A/en not_active Ceased
- 2020-12-01 WO PCT/EP2020/084160 patent/WO2021110697A1/en not_active Ceased
- 2020-12-01 PL PL20819676.6T patent/PL4069199T3/en unknown
- 2020-12-01 EP EP20819676.6A patent/EP4069199B1/en active Active
- 2020-12-01 BR BR112022010626A patent/BR112022010626A2/en unknown
- 2020-12-01 CA CA3162154A patent/CA3162154A1/en active Pending
- 2020-12-01 US US17/756,720 patent/US12502355B2/en active Active
- 2020-12-01 ES ES20819676T patent/ES2977281T3/en active Active
- 2020-12-01 CN CN202080079856.6A patent/CN114727963B/en active Active
- 2020-12-01 MY MYPI2022002810A patent/MY207909A/en unknown
- 2020-12-01 JP JP2022532676A patent/JP7731883B2/en active Active
- 2020-12-01 IL IL293268A patent/IL293268A/en unknown
- 2020-12-01 AU AU2020395495A patent/AU2020395495B2/en active Active
- 2020-12-01 MX MX2022006662A patent/MX2022006662A/en unknown
- 2020-12-02 AR ARP200103346A patent/AR120653A1/en unknown
- 2020-12-02 TW TW109142344A patent/TWI870511B/en active
Also Published As
| Publication number | Publication date |
|---|---|
| EP4069199B1 (en) | 2024-01-17 |
| AU2020395495B2 (en) | 2024-05-09 |
| IL293268A (en) | 2022-07-01 |
| WO2021110697A1 (en) | 2021-06-10 |
| US12502355B2 (en) | 2025-12-23 |
| CN114727963B (en) | 2024-12-27 |
| JP7731883B2 (en) | 2025-09-01 |
| KR20220109430A (en) | 2022-08-04 |
| CA3162154A1 (en) | 2021-06-10 |
| AU2020395495A1 (en) | 2022-07-14 |
| TWI870511B (en) | 2025-01-21 |
| US20230000775A1 (en) | 2023-01-05 |
| ES2977281T3 (en) | 2024-08-21 |
| JP2023505128A (en) | 2023-02-08 |
| EP4069199A1 (en) | 2022-10-12 |
| AR120653A1 (en) | 2022-03-09 |
| CN114727963A (en) | 2022-07-08 |
| BR112022010626A2 (en) | 2022-08-16 |
| MX2022006662A (en) | 2022-07-05 |
| TW202133859A (en) | 2021-09-16 |
| PL4069199T3 (en) | 2024-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2020016659A3 (en) | Multiparticulate formulations of cannabinoids | |
| CO2019003630A2 (en) | Non-protein clostridial toxin compositions | |
| WO2016149028A3 (en) | Epinephrine formulations | |
| MA52965B1 (en) | GIP/GLP1 AGONIST COMPOSITIONS | |
| EP4685160A3 (en) | Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
| MY204993A (en) | Formulations | |
| UY38080A (en) | LOW PH PHARMACEUTICAL FORMULATION | |
| MX395336B (en) | PHARMACEUTICAL PREPARATION OF STABLE ANTI-PD-1 ANTIBODY AND ITS APPLICATION IN MEDICINE. | |
| MX2022010831A (en) | Extended release injectable formulations comprising an isoxazoline active agent, methods and uses thereof. | |
| DK1885336T3 (en) | Suspension formulations comprising an active principle, a surfactant poloxamer or meroxapol agent and a glycol, as well as their use in the manufacture of a medicament for the treatment of eye disorders | |
| AU2019339740A8 (en) | CSF-1R antibody formulation | |
| MX2021013488A (en) | Liquid oral dosage formulations of methylnaltrexone. | |
| TW201613557A (en) | Stable aqueous recombinant protein formulations | |
| MY209656A (en) | Compositions and methods of enhancing 5-hydroxytryptophan bioavailability | |
| EA202190561A1 (en) | AG10 PREPARATIONS | |
| MX2018008868A (en) | Glucomannan containing pharmaceutical compositions with extended release and abuse deterrent properties. | |
| MX2020009935A (en) | Stable aqueous anti-tau antibody formulations. | |
| MX2025012462A (en) | LIPID NANOPARTICLE (LNP) DELIVERY SYSTEMS AND FORMULATIONS | |
| DK1906916T3 (en) | Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a tonicity regulating glycol based agent, use of the composition for the manufacture of a medicament for the treatment of ophthalmic disorders | |
| MX2025010834A (en) | Formulations of an antiviral prodrug | |
| WO2020089942A3 (en) | A liquid injectable composition | |
| PH12017502426A1 (en) | Solid pharmaceutical compositions for treating hcv | |
| MX2022004014A (en) | Lyophilized composition comprising (s)-isopropyl 2-((s)-2-acetamido-3-(1h-indol-3-yl)propanamido)-6-diazo-5-oxoh exanoate for intravenous administration and the use thereof. | |
| MX2023002352A (en) | Mcl-1 inhibitor formulations. | |
| MY155660A (en) | Novel compositons of treatment of essential thrombocythemia |